Advancing drug development in myelodysplastic syndromes

[Display omitted] Myelodysplastic syndromes/neoplasms (MDSs) are heterogeneous stem cell malignancies characterized by poor prognosis and no curative therapies outside of allogeneic hematopoietic stem cell transplantation. Despite some recent approvals by the US Food and Drug Administration, (eg, lu...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood advances 2024-12
Hauptverfasser:	Mina, Alain, McGraw, Kathy L., Cunningham, Lea, Kim, Nina, Jen, Emily Y., Calvo, Katherine R., Ehrlich, Lori A., Aplan, Peter D., Garcia-Manero, Guillermo, Foran, James M., Garcia, Jacqueline S., Zeidan, Amer M., DeZern, Amy E., Komrokji, Rami, Sekeres, Mikkael A., Scott, Bart, Buckstein, Rena, Tinsley-Vance, Sara, Verma, Amit, Wroblewski, Tanya, Pavletic, Steven, Norsworthy, Kelly
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!